Trazimera (a trastuzumab biosimilar) in HER2-positive metastatic breast cancer: Long-term safety and overall survival data

首页> 外文期刊>Intelligence: A Multidisciplinary Journal >Trazimera (a trastuzumab biosimilar) in HER2-positive metastatic breast cancer: Long-term safety and overall survival data

【24h】

Trazimera (a trastuzumab biosimilar) in HER2-positive metastatic breast cancer: Long-term safety and overall survival data

机译：Trazimera（一种曲妥珠单抗生物酸）在HER2阳性转移性乳腺癌中：长期安全和整体生存数据

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Intelligence: A Multidisciplinary Journal》 |2020年第2020期|共2页
作者

展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类心理学;
关键词

相似文献

外文文献
中文文献
专利

1. Trazimera (a trastuzumab biosimilar) in HER2-positive metastatic breast cancer: Long-term safety and overall survival data [J] . Intelligence: A Multidisciplinary Journal . 2020,第期

机译：Trazimera（一种曲妥珠单抗生物酸）在HER2阳性转移性乳腺癌中：长期安全和整体生存数据
2. Long-term survival in HER2-positive metastatic breast cancer treated with first-line trastuzumab: results from the french real-life curie database [J] . Kaczmarek E., Saint-Martin C., Pierga J-Y., Breast cancer research and treatment. . 2019,第3期

机译：用一线曲妥珠单抗治疗的Her2阳性转移性乳腺癌的长期存活：法国现实生活居民数据库的结果
3. The open-label, multinational, multicenter, Phase IIIB umbrella study of subcutaneous trastuzumab with or without chemotherapy or pertuzumab in patients (pts) with HER2-positive early breast cancer (EBC) or metastatic breast cancer (MBC): Pooled analysis of safety data from the UmbHER1 program [J] . Pivot X., Poole C., Martin M., European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR) . 2018,第期

机译：具有或不含化疗或患者（PTS）的皮下曲据（PTS）与HER2阳性早期乳腺癌（EBC）或转移性乳腺癌（MBC）的开放标签，跨国，多中心，阶段IIIB伞研究，包括（PTS）（MBC）：安全数据的汇总分析来自Umbher1程序
4. Elevated WBP2 Expression in HER2-Positive Breast Cancers Correlates with Sensitivity to Trastuzumab-Based Neo-Adjuvant Therapy: A Retrospective and Multicentric Study [C] . Yoon Pin Lim International Molecular Medicine Tri-Conference. . 2019

机译：HER2阳性乳腺癌中的WBP2表达升高与基于曲妥珠单抗的新辅助治疗的敏感性相关：回顾性和多中心研究
5. A phase Ib study of safety and pharmacokinetics of trastuzumab emtansine and pertuzumab in Japanese patients with HER2-positive metastatic breast cancer [D] . NOGUCHI, Emi 2019

机译：Ib期研究曲妥珠单抗氨丹宁和帕妥珠单抗在日本HER2阳性转移性乳腺癌患者中的安全性和药代动力学
6. PF-05280014 (a trastuzumab biosimilar) plus paclitaxel compared with reference trastuzumab plus paclitaxel for HER2-positive metastatic breast cancer: a randomised double-blind study [O] . Mark D. Pegram, Igor Bondarenko, Marina Moreira Costa Zorzetto, 2019

机译：PF-05280014（曲妥珠单抗生物仿制药）加紫杉醇与参考曲妥珠单抗加紫杉醇治疗HER2阳性转移性乳腺癌的比较：一项随机双盲研究
7. Final overall survival analysis of the phase 3 HERITAGE study demonstrates equivalence of trastuzumab-dkst to trastuzumab in HER2-positive metastatic breast cancer [O] . Hope S. Rugo, Eduardo J. Pennella, Unmesh Gopalakrishnan, 2021

机译：第3阶段遗产研究的最终总体存活分析证明了在HER2阳性转移性乳腺癌中的曲妥珠单抗至曲妥珠单抗的等价性

Trazimera (a trastuzumab biosimilar) in HER2-positive metastatic breast cancer: Long-term safety and overall survival data

著录项

相似文献

相关主题

期刊订阅